Actions of Tempus ai (Stir -19.20%)) fall on Wednesday. One of the largest assets in Wood Cathie, the company’s stock, dropped from 18.7% to 2:15 p.m.. The collapse comes like the S&P 500 (^ GSPC -0.56%)) and the Nasdaq Composite (^ Ixic -0.51%)) were mainly flat.
Tempus, a company “Precision Medicine” which operates artificial intelligence (AI) To better treat patients, was the target of a short report in the management of SPRUCE POINT to short -term sale which alleys that stock has up to 60% decrease.
Tempus faces important allegations
The report, published at a time when the market opened today, describes the allegations of Spruce. The most overwhelming understands a history of corporate leadership, in particular the founder Eric Lefkofsky, creating cutting -edge technology companies that make daring allegations that they often fail to support. The report indicates that management leaves companies, having made millions, leaving shareholders “dull” losses or yields.
The report also alleges that Lefkofsky and Tempus Leadership deceive the public as to their use of AI. The report indicates that just before the company has iPo’d, like the media beaten of AI, the company renamed Tempus Labs in Tempus AI. Despite its centrality in the new name, the brand image and public declarations of the company, only 2% of its 2024 revenues came from AI requests. The report alleys that the real capacity of tempus to use AI is largely overestimated.
Image source: Getty Images.
There are reasons to be skeptical
Although there are many other allegations – such as accounting irregularities and weaken relations with the main customers as Astrazeneca – It is important to take it with a grain of salt. The seller runs has a financial participation by seeing the decrease in the price of the tempus action. However, the report is convincing, and even if most allegations prove to be false, I agree with its final evaluation that the stock is already too expensive. I would stay far from Tempus, even if he is one of the favorites of Cathie Wood.
Johnny Rice Has no position in the actions mentioned. The Motley Fool recommends Astrazeneca Plc. The Word’s madman has a Disclosure policy.
